10th week of 2012 patent applcation highlights part 32 |
Patent application number | Title | Published |
20120058038 | Method and Device for Producing Polyphosphoric Acid - A method and device for producing polyphosphoric acid burns a fuel in combustion air in a combustion chamber, sprays a spray fluid comprising substantially pure orthophosphoric acid and undertakes polymerization-condensation of the pure orthophosphoric acid. A polyphosphoric acid in the form of an acid mist accompanied by formation of gases which mix with combustion gases resulting from burning of the fuel is formed to reach a predetermined temperature, wherein the mixture causes sudden lowering of combustion gas temperature. The acid mix is separated from the gas mixture and the polyphosphoric acid is collected at a bottom of the combustion chamber and the gas mixture is outputted via a lower part of the combustion chamber separate from the collection of polyphosphoric acid. | 2012-03-08 |
20120058039 | HIGH PERFORMANCE CATHODE MATERIAL LiFePO4, ITS PRECURSORS AND METHODS OF MAKING THEREOF - In one aspect of the invention, methods of synthesizing iron phosphate precursors and lithium iron phosphate active material usable for a lithium secondary battery include the steps of first forming fine particle iron phosphate precursors hydrated and anhydrous, then forming electrode active material lithium iron phosphate with said iron phosphate precursors. The unique methods are generally efficient and cost effective, as well as stable and scalable for a high performance electrode active material with high capacity, good discharge profile, high electronic conductivity, as well as long cycle life. | 2012-03-08 |
20120058040 | PROCESS FOR PRODUCING POLYCRYSTALLINE SILICON - The invention provides a process for producing polycrystalline silicon, by introducing reaction gases containing a silicon-containing component and hydrogen into reactors to deposit silicon, wherein a purified condensate from a first deposition process in a first reactor is supplied to a second reactor, and is used in a second deposition process in that second reactor. | 2012-03-08 |
20120058041 | GAS GENERATOR AND GAS GENERATION METHOD - A gas generator includes a processing vessel defining a processing space and holding a support body therein, an evacuation system evacuating the processing space; a metal oxide film of a perovskite structure containing oxygen defects formed on the support body, a source gas supplying port supplying a source gas containing molecules of a source compound of carbon dioxide or water into the processing space, a gas outlet port for extracting a product gas containing molecules of a product compound in which oxygen atoms are removed from said source compound, and a heating part heating the support body. | 2012-03-08 |
20120058042 | PHYSICAL SEPARATION AND SEQUESTRATION OF CARBON DIOXIDE FROM THE EXHAUST GASES OF FOSSIL FUEL COMBUSTION - Methods are provided for physically removing all the carbon dioxide from the combustion products of solid, liquid, and gaseous fossil fuels. The combustors operate without excess air to maximize the carbon dioxide at the exhaust, which is compressed with the nitrogen and mixed with pressurized water to dissolve the carbon dioxide in a chamber from which the nitrogen gas is removed. The solution is drained into a second lower pressure chamber from which the carbon dioxide re-evolves as a gas, which is then pressurized for sequestration in limestone formations as calcium bicarbonate. The water is recycled to repeat the separation process, and depressurization of the two gases recovers most of the compression energy. | 2012-03-08 |
20120058043 | PROCESSES AND DEVICES FOR REMOVING RUTHENIUM AS RuO4 FROM RUTHENATE-CONTAINING SOLUTIONS BY DISTILLATION - In processes for removing ruthenium by distilling RuO | 2012-03-08 |
20120058044 | PROCESS OF USING AN IMPROVED FLUE IN A TITANIUM DIOXIDE PROCESS - This disclosure relates to a flue providing improved heat transfer comprising an inner layer and an outer layer, wherein the inner layer comprises a high thermal conductivity ceramic having a thermal conductivity of at least 91 W/m-K (@300K) and a Moh's hardness of at least 6.5, and comprises a plurality of protuberances | 2012-03-08 |
20120058045 | GAS FROM LANDFILL FOR USE IN HYDROGEN PRODUCTION - Methane collected from a landfill is used as a feedstock for the production of hydrogen in a steam methane reformer. This invention provides a green energy feed stock for the hydrogen production that benefits the environment. | 2012-03-08 |
20120058046 | PACKAGED HYDROGEN-GENERATING AGENT, MANUFACTURING METHOD THEREFOR, AND HYDROGEN GENERATION METHOD - Provided is a packaged hydrogen-generating agent, the hydrogen-generating reaction of which is highly stable and repeatable, and which preferably is resistant to influence from changes in the environmental temperature. Also provided are a method for manufacturing said package, and a hydrogen generation method. The packaged hydrogen-generating agent is provided with: a hydrogen-generating agent ( | 2012-03-08 |
20120058047 | METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION - The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers. | 2012-03-08 |
20120058048 | DIRECTED RADIOTHERAPY - The present invention relates enhanced targeting of drug delivery vehicles to vascular endothelial cells | 2012-03-08 |
20120058049 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT - Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula (I), or formula (II); wherein X is OH, C1-C6 alkoxyl, 18F, or 19F; Y and Z are independently selected from a C1-C6 alkyl, CpC6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H, X is not OH. | 2012-03-08 |
20120058050 | LOADED LATEX OPTICAL MOLECULAR IMAGING PROBES CONTAINING LIPOPHILIC LARGE STOKES SHIFT DYES - The present invention relates to a loaded particle comprising at least one fluorescent dye, and in particular, a fluorescent dye with a large Stokes shift. The invention further relates to a method for producing an loaded latex particle, loaded with a fluorescent dye having a large stokes shift. In addition, the present invention relates to latex particles loaded with fluorescent dyes that are organic solvent soluble and insoluble in water. In a preferred embodiment, when the dyes are loaded into the water soluble latex particle, an increase is observed in quantum yield of fluorescence as compared to the quantum yield of the dye in aqueous solvent. | 2012-03-08 |
20120058051 | ANTI-HUMAN ROR1 ANTIBODIES - The invention relates to antibodies having specificity for human ROR1, compositions thereof, and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with aberrant ROR1 expression. | 2012-03-08 |
20120058053 | CARBON NANOHORN MRI CONTRAST AGENTS - A contrast agent characterized in that each of carbon nanohorns forming a carbon nanohorn aggregate has an opening at the side wall or tip, wherein a metal M (at least one metal selected from among paramagnetic metals, ferromagnetic metals, and superparamagnetic metals) or a compound of the metal M is incorporated in or dispersed on each of the carbon nanohorns. A contrast agent characterized in that it contains a Gd oxide. There is provided a contrast agent, which can be mass-produced easily, and satisfies the requirement of low toxicity and enables microscopic diagnoses when used for MRI. A contrast agent characterized in that is contains a carbon nanohorn aggregate. | 2012-03-08 |
20120058054 | GADOLINIUM COMPLEX, METHOD FOR PREPARING SAME, AND MRI CONTRAST AGENT COMPRISING SAME - Disclosed are a gadolinium complex formed by coordination of gadolinium to the diethylenetriaminepentaacetic acid dianhydride (DTPA) moiety of a pullulan-DTPA conjugate formed by an ester bond between pullulan and DTPA, a preparation method thereof, an MRI contrast composition comprising the complex, and a method of providing information for diagnosis of disease using the complex as an MRI contrast agent. The pullulan-DTPA-Gd complex has a long in vivo half-life, low toxicity, and high MRI signal intensity resulting in clear MRI images, compared to prior gadolinium complexes, indicating that it is advantageously used as an MRI contrast agent. In addition, it is possible to obtain MRI images allowing one to differentiate between diseased liver tissue and normal liver tissue, indicating that it is used as an MRI contrast agent for the liver. | 2012-03-08 |
20120058055 | GASTRORENTENTIVE ORAL HIGH DOSE ZINC PREPARATIONS - A method of providing zinc to a subject in need of treatment includes administering to the subject an effective amount of a sustained-release zinc composition. | 2012-03-08 |
20120058056 | TREATMENT OF CUTANEOUS HEMANGIOMA - This invention concerns a method of treating hemangiomas with a beta blocker by applying the beta blocker onto the hemangiomas directly. The invention also concerns a combination therapy by using a beta blocker along with a corticosteroid or an alpha adrenergic receptor agonist for the treatment of hemangiomas. | 2012-03-08 |
20120058057 | Anti-dandruff Agents - The present invention relates to special ammonium carboxylates, their synthesis and application, particularly as anti-dandruff agents. | 2012-03-08 |
20120058058 | COMPOUNDS DERIVED FROM MUSCODOR FUNGI - The present invention relates to novel compounds and compositions and the use of them for the control of fungal and bacterial pathogens, insect pests, acari, nematodes and other invertebrate pests including, but not limited to post-harvest and soil diseases, building mold remediation, and seed and grain sanitation. | 2012-03-08 |
20120058059 | SINGLE PHASE WHITENING DENTIFRICE - The invention provides a single phase whitening dentifrice that includes (i) a whitening agent selected from the group consisting of hydrogen peroxide, a bound peroxide and a solid peroxide (ii) an abrasive and (iii) a substantially anhydrous orally acceptable carrier, for example, polyethylene glycol. The bound peroxide may be hydrogen peroxide and a polymer and/or any peroxide compound and a porous cross-linked polymer, such as polymers of polyvinyl pyrrolidone, polyacrylates, a polymethacrylates, and a polyitaconates. The solid peroxide may be sodium perborate or urea peroxide. The invention also provides methods of whitening the tooth surfaces by contacting the surface with the composition. | 2012-03-08 |
20120058060 | Cationic/Cationogenic Comb Copolymer Compositions and Personal Care Products Containing the Same - Cationic and cationogenic comb copolymers are disclosed along with personal care products that employ them as a modifier that results in increased sensory attributes and increased effectiveness in the deposition of actives and can also act as a thickening agent. The copolymer includes one or more repeating units derived from olefinically unsaturated cationic or cationogenic comonomers and one or more repeating units having the formula | 2012-03-08 |
20120058061 | COSMETIC BASIC COMPOSITION AND ITS USE - The present invention relates to a cosmetic basic composition comprising hydroxypropylmethylcellulose (HPMC) modified with C | 2012-03-08 |
20120058062 | TWO COMPONENT INTERACTIVE EMULSION PRODUCT - The present invention describes, in one aspect, the use of two oppositely charged surfactants as the primary emulsifiers in two separated parts of a product. The emulsifiers are chosen such that when the two parts of the emulsion product are mixed, the emulsifiers react to form water insoluble compounds that are no longer able to function as emulsifiers, thus, the oil phase of the emulsion is precipitated onto the skin along with the emulsifier reaction product. Since none of the deposited materials are water soluble, or capable of functioning as emulsifiers, the deposited oil phase is extremely resistant to being washed off. This technology finds applications in hand and body creams and lotions, baby care products, sunscreens, skin protective products, makeup systems, and automotive and furniture polishes. | 2012-03-08 |
20120058063 | PROCESS FOR TREATING AND/OR FORMING A NON-NEWTONIAN FLUID USING MICROCHANNEL PROCESS TECHNOLOGY - The disclosed invention relates to a process, comprising: conducting unit operations in at least two process zones in a process microchannel to treat and/or form a non-Newtonian fluid, a different unit operation being conducted in each process zone; and applying an effective amount of shear stress to the non-Newtonian fluid to reduce the viscosity of the non-Newtonian fluid in each process zone, the average shear rate in one process zone differing from the average shear rate in another process zone by a factor of at least about 1.2. | 2012-03-08 |
20120058064 | USE OF CHARGED SURFACTANTS FOR REDUCING TEXTILE STAINING BY ANTIPERSPIRANTS - The invention comprises the use of one or more charged surfactants in preparations having an antiperspirant effect for reducing staining in or on clothing and improving improvement the ability of stains to be washed out of the clothing. | 2012-03-08 |
20120058065 | Oil-Based Skin Treatment Composition - The invention provides an oil-based skin treatment composition that contains antibacterial zeolite, an oil component, and glutathione and/or L-cysteine. | 2012-03-08 |
20120058066 | SELF-ASSEMBLING PEPTIDE AND PEPTIDE GEL WITH HIGH STRENGTH - Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a | 2012-03-08 |
20120058067 | COMPOSITIONS FOR TREATING KERATIN-CONTAINING FIBERS AND MAINTAINING DYED FIBER COLOR INTEGRITY - Disclosed are compositions, inter alia, shampoos, conditioners, and restoratives that are effective in preventing further damage to keratin-containing fibers damaged by exposure to oxidative dyeing catalysts, mechanical damage, exposure to UV and visible radiation, and the like. | 2012-03-08 |
20120058068 | COMPOSITIONS FOR REPAIRING AND RESTORING KERATIN-CONTAINING FIBERS - Disclosed are compositions that can be used as an adjunct to regular shampooing and conditioning products, wherein the disclosed compositions provide a means for repairing and restoring keratin-containing fibers to their original condition. | 2012-03-08 |
20120058069 | Cationic Benzoxazine (Co)Polymers - Cationic benzoxazine (co)polymers wherein at least 5% of all nitrogen atoms are in the form of quaternary nitrogen atoms, and to a method for producing said polymers. The invention also relates to a washing and cleaning agent, a textile treatment agent or a cosmetic agent containing at least one cationic benzoxazine (co)polymer according to the invention. | 2012-03-08 |
20120058070 | METHOD FOR PRODUCING A HAIR SHINE COSMETIC, AND HAIR SHINE COSMETIC PRODUCT - A hair shine cosmetic product and a method for producing same are disclosed. The product is composed of sunflower glycerides, water, sunflower seed extract, a plant mixture, preservatives, citric acid and a fragrance, besides silica or Antil 200 (hydrogenated and polyethoxylated glyceryl palmate with 200 ethylene glycol units, combined with polyethoxylated glyceryl cocoate with 7 ethylene glycol units). The production method comprises weighing the components, mixing the sunflower glycerides, water, sunflower seed extract and plant mixture for at least 30 minutes under constant stirring, slowly spraying the silica or Antil 200, heating the resultant mixture to 50° C. and keeping it at this temperature for at least 60 minutes, reducing the temperature to 25-30° C., adding the preservative, citric acid and fragrance. | 2012-03-08 |
20120058071 | HAIR CARE PRODUCT CONTAINING ACETYLPYRIDINIUM SALTS - Cosmetic hair treatment agent comprising, in a cosmetically acceptable carrier, at least one surface-active agent chosen from cationic and/or zwitterionic surfactants, and at least one acetylpyridinium derivative of formula (I) for improving the general condition of the hair, for reducing hair damage in the interior of the hair, and for increasing the elasticity of hair. | 2012-03-08 |
20120058072 | Compositions for Removal of Odors - The present invention provides, in one embodiment, a composition for removing odors. The composition includes, in one embodiment, a salt having at least one of a halogen and an alkaline in an effective amount sufficient to remove odors from the materials when applied thereto. The salt, in an embodiment, may include one of chloride, sodium, magnesium, calcium, potassium, or a combination thereof. A method of making the composition is also provided herein. | 2012-03-08 |
20120058073 | 2-OXASPIRO[5.5]UNDEC-8-ENE Derivatives Useful in Fragrance Compositions - Disclosed are substituted 2-oxaspiro[5.5]undec-8-ene derivatives of formula (I) and their use as odorants. This disclosure relates furthermore to a method of their production and flavour and fragrance compositions comprising them. | 2012-03-08 |
20120058074 | Deodorizing Compositions - The present invention relates to odor-inhibiting compositions comprising water-absorbing polymer particles and at least one oxidase. | 2012-03-08 |
20120058075 | NOVEL METHODS FOR CLEANING A SURFACE - A method of killing and removing bacteria, mold, mildew or fungus from a surface or keratin substrate includes contacting the surface with an aqueous solution containing a multi carboxylic alpha hydroxy acid, a mono carboxylic organic acid and optionally Aloe. The aqueous solution has a pH of less than 2. The method can also be used to deodorize fabrics, surfaces or stagnant water. The method can also be used to treat wounds and skin irritations. | 2012-03-08 |
20120058076 | AESTHETIC TREATMENT OF SCARS AND AGING SKIN - Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include | 2012-03-08 |
20120058077 | BIOSTATIC POLYMER - Methods and compositions effective for at least a week for prevention of microbial colony growth on a surface, for example an inanimate surface, where the surface is covered with a dry or substantially dry film formed from a composition comprising a polyvinyl alcohol and a quaternary ammonium compound. The film may be formed in situ by coating the surface with a solution or emulsion comprising a polyvinyl alcohol and a quaternary ammonium compound and then causing or allowing it to dry or substantially dry. | 2012-03-08 |
20120058078 | ASSAY FOR THE DETECTION OF FACTORS THAT MODULATE THE EXPRESSION OF INGAP - A reporter construct contains mammalian INGAP 5′-regulatory region or a fragment thereof, a minimal promoter element from mammalian INGAP or a heterologous promoter, and a reporter gene. The reporter construct can be used to screen for agents which alone or in combination up-regulate or down-regulate reporter gene expression. Alternatively, the reporter construct can be used to screen for agents that bind to the hamster INGAP 5′-regulatory region or a fragment thereof. | 2012-03-08 |
20120058079 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase - The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives. | 2012-03-08 |
20120058080 | 7-Nitro-2-(3-nitro phenyl)-4H-3,1-benzoxazin-4-one or derivatives thereof for treating or preventing antiviral infections - Surprising antiviral activity of 7-Nitro-2-(3-nitro phenyl)-4H-3,1-benzoxazin-4-one (Compound 1) was reported in the treatment or prevention of viral infections, particularly in combination with other antiviral agents such as interferon and/or ribavarin. | 2012-03-08 |
20120058081 | Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda - The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-λ). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-λ and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-λ | 2012-03-08 |
20120058082 | METHODS AND COMPOSITIONS FOR TREATMENT - The invention provides methods for improving the efficacy and reducing side effects of anti-CD52 antibody treatment. The methods can be used to treat patients who are in need of immunoregulation such as lymphocyte depletion and patients who have cancer. Also included are compositions useful for these methods. | 2012-03-08 |
20120058083 | Therapies for Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Beta - The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-β therapeutics. | 2012-03-08 |
20120058084 | Interferon Alpha Carrier Prodrugs - The present invention relates to a pharmaceutical composition comprising a water-soluble polymeric carrier linked prodrug of interferon alpha, wherein the prodrug is capable of releasing free interferon alpha, wherein the release half life under physiological conditions is at least 4 days. The invention further relates to prodrugs for said pharmaceutical composition and their use for treating, controlling, delaying or preventing a condition that can benefit from interferon alpha treatment, such as hepatitis C. | 2012-03-08 |
20120058085 | Deuterium Modified Benzimidazoles - This invention relates to derivatives of | 2012-03-08 |
20120058086 | COMPOSITIONS, KITS, AND METHODS FOR PROMOTING ISCHEMIC AND DIABETIC WOUND HEALING - Compositions, kits and methods for promoting diabetic wound healing are based on the discovery that SDF-1α specifically upregulates expression of E-selectin in mature endothelial cells (EC), leading to an increase in EC-endothelial progenitor cell (EPC) adhesion and EPC homing. Methods for promoting healing of a wound in a diabetic subject include providing a therapeutically effective amount of a composition including E-selectin protein or a nucleic acid encoding E-selectin protein, and optionally, an agent that specifically upregulates E-selectin expression (e.g., SDF-1α). The methods can also include administering hyperbaric oxygen treatment to the subject. Administering the composition to the subject results in migration of bone marrow-derived progenitor cells to the wound, accelerated wound healing, and upregulation of E-selectin expression in the subject. | 2012-03-08 |
20120058087 | DIAGNOSIS OF ENDOMETRITIS - The present invention relates to methods for diagnosing and treatment of a dormant infection of at least one pathogen. The invention further relates to a composition comprising an anti-dormancy factor as well as to said composition for use in a method of diagnosis or treatment and also to a method for manufacturing said composition. The invention further relates to a kit of parts comprising, inter alia, said composition. The invention also relates to a method for activating a dormant infection. | 2012-03-08 |
20120058088 | Resveratrol-Containing Compositions And Methods Of Use - A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, and one or more additional antioxidants such as phenolic antioxidants or vitamin D. | 2012-03-08 |
20120058089 | TREATMENT OF ORGAN INJURIES AND BURNS USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom. | 2012-03-08 |
20120058090 | Alimentary Protein-Based Scaffolds (APS) for Wound Healing, Regenerative Medicine and Drug Discovery - The invention provides engineered biomaterials derived from plant products. The engineered biomaterials are useful for biomedical applications. The engineered biomaterials are able to support the growth of animal cells. | 2012-03-08 |
20120058091 | DIAGNOSTIC AND THERAPEUTIC TREATMENTS RELATED TO MITOCHONDRIAL DISORDERS - The invention is based in part on the discovery that chromosomal disorders such as Down Syndrome can be diagnosed by assessing maternal mitochondrial status. Thus the invention relates to diagnostic and therapeutic methods and related products for chromosomal disorders such as Downs Syndrome, for example, for identifying a risk of fetal Downs Syndrome and methods of mitigating that risk. The methods also are useful for other therapies where it is desirable to manipulate mitochondria such as tissue generation. | 2012-03-08 |
20120058092 | PROCESS FOR THE PREPARATION OF A COMPOSITION OF GENETICALLY MODIFIED HEMATOPOIETIC PROGENITOR CELLS - Described are compositions and methods relating to gene therapy, particularly as applied to hematopoietic progenitor (HP) cells, to transduced cells and methods of obtaining them, and to methods of using them to provide prolonged engraftment of modified hematopoietic cells in human subjects. The invention particularly relates to ex vivo gene therapy of HP cells for treatment or prevention of HIV infection. | 2012-03-08 |
20120058093 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS - Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit. | 2012-03-08 |
20120058094 | COMPOSITIONS AND METHODS FOR TREATING OBESITY AND RELATED DISORDERS BY CHARACTERIZING AND RESTORING MAMMALIAN BACTERIAL MICROBIOTA - The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (HPMC) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota. | 2012-03-08 |
20120058095 | OILY SUSPENSION CONTAINING PROBIOTIC BACTERIA FOR PAEDIATRIC USES - The present invention refers to an oily suspension containing probiotic bacteria, particularly suitable for paediatric use. | 2012-03-08 |
20120058096 | COMPOSITIONS AND METHODS FOR GENERATING INTERLEUKIN-35-INDUCED REGULATORY T CELLS - Compositions and methods are provided for generating T cells having a regulatory phenotype from conventional T (T | 2012-03-08 |
20120058097 | COMPOSITIONS INCLUDING A SODIUM CHANNEL BLOCKER AND A B VITAMIN MOLECULE AND METHODS OF USE THEREOF - The invention generally relates to compositions including a sodium channel blocker and a B vitamin molecule and methods of use thereof. In certain embodiments, the invention provides compositions that include a sodium channel blocker and a B vitamin molecule. In other embodiments, the invention provides methods for treating a subject having a psychological disorder, a neurological disorder, a neurodengerative disorder, and/or a disorder associated with pain involving administering to the subject a sodium channel blocker and a B vitamin molecule. | 2012-03-08 |
20120058098 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described. | 2012-03-08 |
20120058099 | USE OF HYPOXANTHINE FOR PROMOTION OF NEURONAL OUTGROWTH - Disclosed herein is a method of promoting neuronal outgrowth in a neuron. The method comprises contacting the neuron with an effective amount of hypoxanthine, to thereby promote neuronal outgrowth of the neuron. The hypoxanthine may be contacted in the absence of xanthine oxidase and/or in the absence of exogenous nerve growth factor (NGF), and/or in the absence of exogenous D-mannose, and/or in the absence of exogenous oncomodulin, and/or in the absence of exogenous TGF-B. The neuron may be an optic nerve neuron or a retinal neuron and/or an injured neuron. Neurons may be from the central nervous system (CNS) or the peripheral nervous system (PNS). The methods are useful for treating an injured neuron, for example to an optic nerve neuron, resulting from branch and central vein/artery occlusion, trauma, edema, angle-closure glaucoma, open-angle glaucoma. Methods of treatment of various neurological injuries and diseases, as well as therapeutic compositions, are also disclosed. | 2012-03-08 |
20120058100 | MODULATION OF DRUG RELEASE RATE FROM ELECTROSPUN FIBERS - Disclosed are co-electrospun polymeric fibers comprising polymers comprising pharmaceutically active agents and/or biologically active agents and capable of release at a combined release rate. Also disclosed are processes for preparing polymeric fibers capable of release at a combined release rate. Also disclosed are processes of modulating delivery rate of pharmaceutically active agents and/or biologically active agents. Also disclosed are processes of delivering pharmaceutically active agents and/or biologically active agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2012-03-08 |
20120058101 | TREATMENT OF HUMAN OR ANIMAL BODY SURFACE INFECTION - A method of treatment of a human or animal body surface infection, particularly a fungal infection, comprises applying an aqueous liquid to the infected body surface, e.g. nail region, followed by applying a dressing comprising a source of hydrogen peroxide. Also provided is a combination of the liquid and dressing for use in the method. | 2012-03-08 |
20120058102 | PHARMACOLOGICALLY INDUCED TRANSGENE ABLATION SYSTEM - The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as “PITA” (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript. | 2012-03-08 |
20120058103 | COMPOSITION OF INDIVIDUAL PROTEOLYTIC ENZYMES - The invention relates to bioengineering, in particular to producing a composition of individual enzymes exhibiting the extended range of proteolytic activity, thereby enabling the composition to hydrolyse protein substrates up to individual amino acids. The composition contains at least two proteases, the molecular mass of which ranges from 23 to 36 kilodaltons and which have the following N-terminal amino acid sequences: I V G G T E V T P G E I P Y Q L S L Q D-I V G E V T P G E I P Y Q L S F Q D-I V G G Q E A S P G S W P X Q V G L F F-E A T S G Q F P Y Q X S F Q D-I V G G Q E A T P H T W V H Q V A L F E A T P H T X V H Q A L F I-A M D X T A Y X D Y D E I Q A X L K N T F E E I N S I L D G V-A A I L G D E Y L X S G G V V P Y V F G-Medicinal and cosmetic means containing the inventive composition of individual highly purified proteolytic enzymes in the form of an active agent make it possible to reduce the concentration of the composition during the use thereof due to the higher enzymatic activity and do not generate allergic reactions during a long term use. In addition, the composition formulation can be optimised (also standardised) with respect to a patient, thereby increasing the efficiency of the composition and reducing side effects of the use thereof. | 2012-03-08 |
20120058104 | USE OF A FERMENTED SOY EXTRACT AS A PREBIOTIC COMPOSITION - The present invention relates to use of a fermented soy extract as a prebiotic composition to protect beneficial bacteria in the gastrointestinal tract of an animal. Particularly, the fermented soy extract of the invention exhibits the prebiotic activity even under an antibiotic treatment. Also disclosed is combined use of an antibiotic and the fermented soy extract of the invention, which has advantages over administration of the antibiotic alone, such as decreasing the effective dose of the antibiotic and/or reducing side effects resulting from the antibiotic treatment. | 2012-03-08 |
20120058105 | METHOD OF TREATMENT OF VASCULAR COMPLICATIONS - The present invention provides methods for the prevention or treatment of one or more vascular complication(s) in a subject at risk of developing diabetes mellitus, impaired glucose tolerance and/or hyperglycemia or a subject suffering from diabetes mellitus, impaired glucose tolerance and/or hyperglycemia, wherein an amount of a composition effective to inhibit, repress, delay or otherwise reduce expression and/or activity and/or level of TXNIP and/or an amount of a composition effective to induce, enhance or otherwise increase expression and/or activity and/or level of TRX is/are administered to a subject in need thereof. The present invention also provides methods for identifying and isolating modulators of TXNIP expression and/or activity and/or level and/or TRX expression and/or activity and/or level for use in such therapeutic and prophylactic methods. | 2012-03-08 |
20120058106 | NOVEL CANCER-ASSOCIATED ANTIGEN - The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits. | 2012-03-08 |
20120058107 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS - The present invention relates to pyrrolo[3,2-c]pyridine-4-one 2-indolinone compounds of Formula (I) and their pharmaceutically acceptable salts thereof, wherein R | 2012-03-08 |
20120058108 | METHODS AND USES INVOLVING GENETIC ABERRATIONS OF NAV3 AND ABERRANT EXPRESSION OF MULTIPLE GENES - The present invention relates to the fields of genetics and oncology and provides methods for detecting tumors as well as methods for treating patients and predicting the prognosis to a patient. Specifically, the present invention relates to a method of demonstrating the malignant character of a tumor or cell subpopulation in a subject, to a method of predicting a prognosis, to a method of treating a subject having a tumor with NAV3 copy number change and with over expression of at least one gene or gene product selected from specific lists, and to a method of selecting a treatment to a subject. The present invention also relates to uses of NAV3 gene or gene product and at least one gene and/or gene product selected from specific lists for demonstrating the malignant character of a tumor or cell sub-population, for predicting a prognosis to a subject, for selecting a treatment to a subject, and for cancer therapy in a subject having a tumor with NAV3 copy number change. Furthermore, the present invention also relates to a use of an antagonist, antibody or inhibitory molecule of at least one gene and/or gene product selected from specific lists for cancer therapy in a subject. Still, the present invention relates to a diagnostic kit comprising tools for detecting NAV3 copy number change in a biological sample and tools for detecting over expression of at least one gene or gene product selected from specific lists in a biological sample. The present invention also relates to a use of a diagnostic kit of the invention for demonstrating the malignant character of a tumor or cell subpopulation, for predicting a prognosis to a subject with a colorectal tumor, brain tumor or tumor of epidermal keratinocytes and for selecting a treatment to a subject with a colorectal tumor, brain tumor or tumor of epidermal keratinocytes. | 2012-03-08 |
20120058109 | REELIN RESCUES COGNITIVE FUNCTION - Disclosed are methods of influencing, and enhancing, cognitive function by increasing, and/or preventing interference with, Reelin levels as well as Reelin signaling. Cognitive function is improved, in a subject in need thereof, by administering a therapeutically effective amount of Reelin, a Reelin-specific modulator or an agonist of a lipoprotein receptor to the subject. The lipoprotein receptor can be selected from candidates such as ApoER2 and VLDLR. As disclosed herein, agonists of the lipoprotein receptor for use with the inventive method include APC, Sep and Fc-RAP. In addition to administering exogenous Reelin, a Reelin-specific modulator, such as a recombinant Reelin fragment, can be used to increase Reelin levels and/or signaling. | 2012-03-08 |
20120058110 | Method for Predicting the Responsiveness to an Anti-TNF Alpha Antibody Treatment - The present invention relates to a method for predicting the responsiveness of a patient to an anti-TNFα antibody treatment. | 2012-03-08 |
20120058111 | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them - The present invention is directed to a sialylated isolated antibody specific for an antigen selected from autoimmune antigens, allergens, MHC molecules or Rhesus factor D antigen, comprising an Fc-portion of IgG type, and exhibiting a sialic acid residue at the Fc-portion for use in treatment and/or prophylaxis of autoimmune disease, allergy, transplant rejection or Rhesus factor D reactivity and to methods of producing such an antibody. | 2012-03-08 |
20120058112 | ANTIBODIES - The combination of an IGF-1R antagonist such as a humanized antibody and an anti-proliferative drug is described. In a preferred embodiment, the present invention describes the combination of an IGF-1R antibody and an anti-proliferative drug belonging to the EGFR-inhibitor class, which is preferably erlotinib. The combination according to the present invention is useful for the treatment of tumours, including IGF-1R and/or EGFR mediated or dependent tumours. | 2012-03-08 |
20120058113 | CANCER TREATMENT METHOD - A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines. | 2012-03-08 |
20120058114 | ERBB2 antibodies comprising modular recognition domains - Antibodies containing one or more modular recognition domains (MRDs) that can be used to target the antibodies to specific sites are described. The use of antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also described. | 2012-03-08 |
20120058115 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 2012-03-08 |
20120058116 | FGFR1C ANTIBODY COMBINATIONS - The invention relates to combinations of FGFR1c antagonists with agonist peptides and provide dual targeting proteins which bind to FEFR1c comprising an antigen binding protein which is capable of binding to FGFR1c and which is linked to one or more agonist peptides, methods of making such constructs and uses thereof, particularly in treating obesity. | 2012-03-08 |
20120058117 | NEUROPILIN-1 INHIBITORS - The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or the metastatic potential of specific tumor cells. Additionally, a method is provided that allows identifying molecules, which interfere with the functionality of neuropilin-1. Furthermore, a method is provided that allows determining whether a naturally occurring tumor cell depends on functional neuropilin-1 for its invasiveness and/or metastatic potential. | 2012-03-08 |
20120058118 | A-BETA BINDING POLYPEPTIDES - The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease. | 2012-03-08 |
20120058119 | HUMAN TUMOR NECROSIS FACTOR TR21 AND METHODS BASED THEREON - The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 activity. | 2012-03-08 |
20120058120 | Targets for Growth Factor Signalling and Methods of Therapy - Methods of screening or designing therapeutic agents effective for the treatment of a transglutaminase-associated disease, disorder and/or condition are provided which include determining whether a candidate agent can modulate an interaction between a transglutaminase and an insulin-like growth factor and/or a member of the IGF family of receptors. Also provided are pharmaceutical compositions and methods of treatment using said pharmaceutical compositions. | 2012-03-08 |
20120058121 | METHODS AND COMPOSITIONS FOR TREATING LUPUS - The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the compound is in an amount less than sufficient to substantially inhibit cyclin dependent kinases. | 2012-03-08 |
20120058122 | Antibodies Directed to HER-3 and Uses Thereof - The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin. | 2012-03-08 |
20120058123 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS - Described herein are compounds that are antagonists of PGD | 2012-03-08 |
20120058124 | INFLUENZA VIRUS-NEUTRALIZING ANTIBODY AND SCREENING METHOD THEREFOR - Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody. | 2012-03-08 |
20120058125 | METHODS RELATING TO PERIPHERAL ADMINISTRATION OF NOGO RECEPTOR POLYPEPTIDES - This invention relates to methods of treating diseases involving accumulation of Aβ plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of increasing the plasma to brain ratio of Aβ peptide and enhancing Aβ peptide clearance via peripheral administration of soluble Nogo receptor polypeptides. This invention also provides methods of improving memory function or inhibiting memory loss via the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of decreasing the size and number of Aβ plaques in a mammal via peripheral administration of soluble Nogo receptor polypeptides. | 2012-03-08 |
20120058126 | ANTI-VEGFR-3 ANTIBODY COMPOSITIONS - The present invention provides anti-VEGFR-3 monoclonal antibodies, pharmaceutical compositions containing said antibodies and uses of said antibodies in the treatment of disease. | 2012-03-08 |
20120058127 | PAR2 Agonists for Use in the Treatment or Prevention of Influenza Virus Type A Infections - The present invention provides methods and compositions (such as pharmaceutical compositions) for treating or preventing influenza virus type A infections. More particularly, the invention relates to a PAR2 agonist for use in the treatment or prevention of an influenza virus type A infection. | 2012-03-08 |
20120058128 | ANTI- INTEGRIN ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 2012-03-08 |
20120058130 | COMPOSITIONS AND METHODS FOR DIAGNOSING, TREATING, AND PREVENTING PROSTATE CONDITIONS - Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN). | 2012-03-08 |
20120058131 | PTA089 PROTEIN - The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer, for monitoring the effectiveness of bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer or skin cancer treatment, and for drug development. | 2012-03-08 |
20120058132 | Treatment of glycogen storage disease type II - Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II. | 2012-03-08 |
20120058133 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF - The present invention provides novel methods for modulating Th 17-mediated immune responses using aminoacyl tRNA synthetase inhibitors. Inhibition of aminoacyl tRNA synthetase inhibitors activates an amino acid starvation response (AAR) and can produce beneficial therapeutic effects. In some embodiments, aminoacyl tRNA synthetase inhibitors are used to treat disorders such as autoimmune diseases, graft rejection, infections, fibrosis, and inflammatory diseases. | 2012-03-08 |
20120058134 | METHOD FOR FERMENTATION AND CULTIVATION, FERMENTED PLANT EXTRACT, FERMENTED PLANT EXTRACT POWDER, AND COMPOSITION CONTAINING THE EXTRACT OF FERMENTED PLANT - For the purpose of providing a method of safely and inexpensively producing a fermented plant extract containing an immunopotentiator at a high concentration, the method for fermentation and culture of the present invention ferments a plant component such as wheat flour using | 2012-03-08 |
20120058135 | Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase - This invention relates to the identification and characterization of racemases and definition of protein signatures of these racemases. More particularly, this invention relates to the identification of nucleic acid molecules encoding a peptide consisting of a motif characteristic of the protein signatures, and to the peptides consisting of these motifs and more specifically SEQ ID NOS: 1-4. This invention also relates to antibodies specific for the peptides and to immune complexes of these antibodies with the peptides. Further, the invention relates to methods and kits for detecting racemases using the nucleic acid molecules of the invention, as well as the peptides consisting of the motifs and antibodies to these peptides. | 2012-03-08 |
20120058136 | NON-SPLICING VARIANTS OF gp350/220 - Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins. | 2012-03-08 |
20120058137 | EFFICIENT TRANSPORT INTO WHITE BLOOD CELLS - The present invention relates to the use of specific transporter cargo conjugate molecules for the transport of a substance of interest (cargo molecule) into white blood cells. Said transporter cargo conjugate molecules may be used for the treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood cells. The present invention also relates to manufacture of said transporter cargo conjugate molecules, to a method of transporting a substance of interest (cargo) into a white blood cell and to a white blood cell comprising said transporter cargo conjugate molecules or fragments thereof. | 2012-03-08 |
20120058138 | Novel Adenovirus Vectors - An adenoviral vector comprising a promoter further comprising a fragment of the 5′ untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumour antigen for use as a medicament. | 2012-03-08 |
20120058139 | NOVEL MULTIMODULAR ASSEMBLY USEFUL FOR INTRACELLULAR DELIVERY - A stabilized multimodular assembly for intracellular delivery comprising a complex of at least one cationic transfection agent and of at least one negatively charged macromolecule, wherein the complex has a theoretical charge ratio ranging from about 0 to about 4, and an efficient amount of at least one amphiphilic block co-polymer acting as a steric colloidal stabilizer with respect to the complex, the block co-polymer having hydrophilic and hydrophobic blocks wherein at least one hydrophilic block is conjugated with at least one targeting ligand. | 2012-03-08 |